TecMed Unveils Unparalleled Accuracy in Blood Glucose Measurement - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
TecMed Unveils Unparalleled Accuracy in Blood Glucose Measurement TecMed, Inc., a leading intellectual property (IP) innovator in blood glucose measurement technology has introduced optical-based IP technology-- with demonstrated accuracy improvement of 40 to 50% over current "Gold Standard" technologies.


TecMed Unveils Unparalleled Accuracy in Blood Glucose Measurement

TecMed, Inc., a leading intellectual property (IP) innovator in blood glucose measurement technology has introduced optical-based IP technology-- with demonstrated accuracy improvement of 40 to 50% over current "Gold Standard" technologies.

PR Newswire

CHEYENNE, Wyo., Feb. 19, 2014 /PRNewswire/ -- What began 18 years ago as a spin off from an optical materials research company has become a competitive and robust medical technology IP company with a portfolio of solutions to blood glucose management problems.  Today, TecMed, Inc. is an innovative IP company with ground-breaking, proven and patented IP solutions for safe, accurate, automated, real-time blood glucose measurement.  In more than 30 blind and double-blind human studies, TecMed's optical measurement technology has demonstrated a 40-50% improvement in accuracy over clinical point of care "Gold Standard" instruments and methods. 

(Logo: http://photos.prnewswire.com/prnh/20140219/LA67401LOGO)

Blood glucose measurement and monitoring markets are responding to demands from healthcare professionals, hospitals, regulatory agencies, patient advocacy groups, and patients for affordable technologies that improve patient outcomes and reduce healthcare costs.  TecMed's innovative IP provides solutions for known problems regarding accuracy, frequency of measure, timeliness of data, excessive labor costs, the need for calibration and/or laboratory data verification, and costly disposables.   Together, these integrated achievements provide an unparalleled and cost effective solution for patient blood glucose measurement in perioperative and critical care settings.

TecMed's patented IP solutions are based on unique optical measurements that are consistent, accurate, real-time, and provide the frequency of measure required for therapeutic management decisions by healthcare professionals.  Advantageously, the optical measurement technology has been designed for inexpensive manufacturing and user automation.  TecMed's IP portfolio is protected by four issued patents containing over 30 independent claims, with several more in varying stages of review, and a written recommendation from the international patent examiner for approval of TecMed's international application.

About TecMed, Inc.
Founded in 1995, TecMed is a privately-held intellectual property company incorporated in the State of Wyoming, organized to create innovative technologies, conduct original research, and advance development in the field of medically-related measurement technologies.  TecMed's fundamental business model relies on the formation of outside business relationships in the medical device and healthcare industries with a primary focus on licensing its IP solutions in blood glucose measurement technology.   

Media Contact:
TecMed, Inc.
(O) 307-509-9653
(E-mail) tecmed@tecmed.com
http://www.tecmed.com

SOURCE TecMed, Inc.

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
88%
Borrow lightly from EMA's pathway program?
4%
Create entirely its own pathway program?
8%
View Results
Untitled Document

Click here